Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Pharm Des. 2009;15(32):3734-41.

Arrhythmia pharmacogenomics: methodological considerations.

Author information

1
Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232-0575, USA. dan.roden@vanderbilt.edu

Abstract

Abnormalities of cardiac rhythm are common clinical problems, resulting in symptoms such as palpitations, breathlessness, stroke, and sudden death. Drugs used to treat arrhythmias have variable actions ranging from completely effective to serious adverse effects, including (paradoxically) sudden death due to drug-induced arrhythmias. Experiments to define the genetic basis for arrhythmia susceptibility and variable responses to antiarrhythmic therapies rely on precise clinical phenotyping. Initial studies used candidate gene approaches, but are now turning to contemporary methods such as genome-wide association. Identification of loci for arrhythmia susceptibility in turn provide a starting point for both understanding underlying biologic pathways as well as improved selection appropriate therapies.

PMID:
19925424
PMCID:
PMC2788624
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Bentham Science Publishers Ltd. Icon for PubMed Central
    Loading ...
    Support Center